PARTNER

Putting men's preferences at the centre of the doctor-patient relationship: the Prostate cancer treatment preferences (PARTNER) test

Prostate cancer (PCa) affects 1 in 10 men and is the most common cancer amongst men in UK. Usually men with localised PCa can choose between several treatment options, such as active surveillance, radiation therapy, or surgery. Different treatments are associated with different risks and types of side effects including urinary incontinence, bowel function, and erectile dysfunction. There is no overall best treatment for localised PCa in terms of cancer control. Therefore, treatment choice should depend on men’s views about the different harms and benefits of each treatment. This means men face a difficult decision that will affect their quality of life. This project will develop a new tool that can easily be used by both men and health care professionals, which will improve communication by identifying men’s preferences for PCa treatment. The tool will achieve two goals: (i) to help men identify what matters most to them by asking them to think about the PCa treatment in a simple, structured way; (ii) to communicate information about men’s preferences to consultants.

HERU researchers involved in this research project: Verity Watson

External collaborators: Krucien, N. (Evidera); MacLennan, S., MacLennan, S.J., N’Dow, J. (Institute of Health Sciences, University of Aberdeen); and Ahmed, H. (Imperial College London)